Race, Ethnicity, Ancestry, and Pharmacogenetics

Duke University, Durham, NC, USA.
Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine (Impact Factor: 1.62). 03/2010; 77(2):133-9. DOI: 10.1002/msj.20168
Source: PubMed


Pharmacogenetics is the study of how genetic variation influences the response to drugs. The concepts of race, ethnicity, and ancestry have long had a strong influence on pharmacogenetic discovery and on our understanding of population-level differences in drug response. The primary goal of pharmacogenetics, however, is to identify the individual genetic determinants of drug activity so that therapy can be tailored to the individual patient. This article describes the relationship between the concepts of race, ethnicity, and ancestry and how these concepts have been applied to pharmacogenetics, and it provides examples of the benefits and pitfalls associated with the use of racial or ethnic labels in genetic studies. The future of pharmacogenetics, including the study of rare genetic variation and what this means for racial or ethnic disparities in pharmacogenetic discovery, is also discussed.

25 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Membrane transporters play a critical role in drug response as they provide the targets for many commonly used drugs and are major determinants of drug absorption, distribution, and elimination. Most of them belong to one of the two major super-families of membrane transport proteins, the ATP-binding cassette (ABC) transporters, and the solute carrier (SLC) transporters. They are subject to both genotypic and phenotypic polymorphisms, and variation in drug transporters may be the reason for inter-individual variability in pharmacokinetic disposition, efficacy, and toxicity of drug transporter substrates. The growing number of publications reporting genetic population data for the solute carrier transporters in particular shows their importance, as well as the increased interest in investigating them in most recent pharmaco-genetics/genomics research projects. These publications range from reporting baseline frequency distributions of SNPs of genes important in drug transport, discovering new genetic variants of these genes, and/or describing genotyping projects to identify probable responders or non-responders to therapy, or to predict exposure levels in different patients. This paper reviews the solute carrier transporters and highlights the fact that there is much to be learnt from characterizing human genomic variation in South Africa and sub-Saharan Africa, especially with regards to health applications. Genomic diversity in this region is indeed relatively under-studied despite being home to significant portion of human genomic diversity. Human genetic variation has implications on a broad range of biological and medical disciplines. For this reason, the study of human genetic diversity is relevant to a variety of research areas including human and popula-tion genetics, molecular biology, evolutionary biology, biological anthropology, health sciences and clinical medicine. The vast extent of inherited variation in the
    AFRICAN JOURNAL OF BIOTECHNOLOGY 12/2010; 9(54):9191-9195. · 0.57 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The rapid progress currently being made in genomic science has created interest in potential clinical applications; however, formal translational research has been limited thus far. Studies of population genetics have demonstrated substantial variation in allele frequencies and haplotype structure at loci of medical relevance and the genetic background of patient cohorts may often be complex. To describe the heterogeneity in an unselected clinical sample we used the Affymetrix 6.0 gene array chip to genotype self-identified European Americans (N = 326), African Americans (N = 324) and Hispanics (N = 327) from the medical practice of Mount Sinai Medical Center in Manhattan, NY. Additional data from US minority groups and Brazil were used for external comparison. Substantial variation in ancestral origin was observed for both African Americans and Hispanics; data from the latter group overlapped with both Mexican Americans and Brazilians in the external data sets. A pooled analysis of the African Americans and Hispanics from NY demonstrated a broad continuum of ancestral origin making classification by race/ethnicity uninformative. Selected loci harboring variants associated with medical traits and drug response confirmed substantial within- and between-group heterogeneity. As a consequence of these complementary levels of heterogeneity group labels offered no guidance at the individual level. These findings demonstrate the complexity involved in clinical translation of the results from genome-wide association studies and suggest that in the genomic era conventional racial/ethnic labels are of little value.
    PLoS ONE 05/2011; 6(5):e19166. DOI:10.1371/journal.pone.0019166 · 3.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This institutional retrospective review studied Ewing sarcomas from 1987-2011. Among 135 patients, 127 (19 Hispanic and 108 white/non-Hispanic) were analyzed (excluding small sample sized groups) finding 15% Hispanic, 85% non-Hispanic, 27% <18 years, 21% >40 years and 1-272 months follow-up (median 41). Age was significantly associated with overall survival (OS) (p = 0.01), whereby <18 years had a higher probability of 5-year survival (OS 61%) than >40 years (OS 37.6%). Ethnicity was marginally statistically significant (OS, p = 0.065); whereby median survival was clinically significant (white non-Hispanic 63 months and Hispanic 23 months). Hispanic ethnicity and older age are independent poor prognostic factors.
    Fetal and pediatric pathology 10/2012; 32(4). DOI:10.3109/15513815.2012.721480 · 0.48 Impact Factor
Show more